Pleiotropic effects of statins
暂无分享,去创建一个
[1] R. Paoletti,et al. Simvastatin but not pravastatin inhibits the proliferation of rat aorta myocytes. , 1991, Pharmacological research.
[2] H. Wada,et al. Hypercoagulable state in patients with hypercholesterolemia: effects of pravastatin. , 1992, Clinical therapeutics.
[3] P. D. de Wilde,et al. The effect of cholesterol reduction on the endothelial function and progression of atherosclerosis in WHHL rabbits. , 1993, Atherosclerosis.
[4] E. Donetti,et al. HMG CoA reductase inhibitors. In vivo effects on carotid intimal thickening in normocholesterolemic rabbits. , 1993, Arteriosclerosis and thrombosis : a journal of vascular biology.
[5] G. Butti,et al. In vivo enhanced antitumor activity of carmustine [N,N'-bis(2-chloroethyl)-N-nitrosourea] by simvastatin. , 1995, Cancer research.
[6] D. Waters,et al. Hyperlipidemia and coronary disease. Correction of the increased thrombogenic potential with cholesterol reduction. , 1995, Circulation.
[7] L. Yeatman,et al. Effect of pravastatin on outcomes after cardiac transplantation. , 1995, The New England journal of medicine.
[8] C. Ballantyne,et al. Levels of Soluble Cell Adhesion Molecules in Patients With Dyslipidemia , 1996 .
[9] S. Hulley,et al. Carcinogenicity of lipid-lowering drugs. , 1996, JAMA.
[10] T. Totsuka,et al. Inhibitory effect of fluvastatin, an HMG-CoA reductase inhibitor, on the expression of adhesion molecules on human monocyte cell line. , 1996, International journal of immunopharmacology.
[11] S. Basili,et al. Simvastatin reduces monocyte-tissue-factor expression type IIa hypercholesterolaemia , 1997, The Lancet.
[12] A. Michael,et al. Reduced platelet aggregation after fluvastatin therapy is associated with altered platelet lipid composition and drug binding to the platelets. , 2003, British journal of clinical pharmacology.
[13] A. Marais,et al. Atorvastatin: an effective lipid-modifying agent in familial hypercholesterolemia. , 1997, Arteriosclerosis, thrombosis, and vascular biology.
[14] R. Collins,et al. Randomized placebo-controlled study of the effects of simvastatin on haemostatic variables, lipoproteins and free fatty acids. The Oxford Cholesterol Study Group. , 1997, European heart journal.
[15] C. Wiedermann,et al. Mevalonate-dependent inhibition of transendothelial migration and chemotaxis of human peripheral blood neutrophils by pravastatin. , 1997, Circulation research.
[16] E. Tremoli,et al. Vastatins inhibit tissue factor in cultured human macrophages. A novel mechanism of protection against atherothrombosis. , 1997, Arteriosclerosis, thrombosis, and vascular biology.
[17] D. Granger,et al. Effects of fluvastatin on leukocyte-endothelial cell adhesion in hypercholesterolemic rats. , 1997, Arteriosclerosis, thrombosis, and vascular biology.
[18] C. Cimminiello,et al. Fluvastatin and tissue factor pathway inhibitor in type IIA and IIB hyperlipidemia and in acute myocardial infarction. , 1997, Thrombosis research.
[19] J. Simons,et al. Effects of atorvastatin monotherapy and simvastatin plus cholestyramine on arterial endothelial function in patients with severe primary hypercholesterolaemia. , 1998, Atherosclerosis.
[20] R. Schmieder,et al. Vasodilatory Capacity of Forearm Resistance Vessels Is Augmented in Hypercholesterolemic Patients After Treatment with Fluvastatin , 1998, Angiology.
[21] S. Katznelson,et al. The inhibitory effects of pravastatin on natural killer cell activity in vivo and on cytotoxic T lymphocyte activity in vitro. , 1998, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.
[22] M. Pfeffer,et al. Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events (CARE) Investigators. , 1998, Circulation.
[23] I. Tsuji,et al. Comparison of plasma tissue factor levels in unstable and stable angina pectoris. , 1998, The American journal of cardiology.
[24] T. Hayek,et al. Interactions of platelets, macrophages, and lipoproteins in hypercholesterolemia: antiatherogenic effects of HMG-CoA reductase inhibitor therapy. , 1998, Journal of cardiovascular pharmacology.
[25] J. Navarro-Antolín,et al. Effects of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors, atorvastatin and simvastatin, on the expression of endothelin-1 and endothelial nitric oxide synthase in vascular endothelial cells. , 1998, The Journal of clinical investigation.
[26] R. Schmieder,et al. Increased bioavailability of nitric oxide after lipid-lowering therapy in hypercholesterolemic patients: a randomized, placebo-controlled, double-blind study. , 1998, Circulation.
[27] J. Tardif,et al. Cholesterol Reduction Rapidly Improves Endothelial Function After Acute Coronary Syndromes , 1998 .
[28] J. Egido,et al. HMG-CoA reductase inhibition by atorvastatin reduces neointimal inflammation in a rabbit model of atherosclerosis. , 1998, Journal of the American College of Cardiology.
[29] B. Melichar,et al. Growth inhibitory effects of aromatic fatty acids on ovarian tumor cell lines. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.
[30] A. Gotto,et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. , 1998, JAMA.
[31] Long-term effects of stent implantation in patients with symtomatic myocardial bridges , 1998 .
[32] D. Black. Statins and fibrinogen , 1998, The Lancet.
[33] R. Vogel. Cholesterol lowering and endothelial function. , 1999, The American journal of medicine.
[34] R. Kriwacki,et al. Structural basis for LFA-1 inhibition upon lovastatin binding to the CD11a I-domain. , 1999, Journal of molecular biology.
[35] M. Minden,et al. Increased sensitivity of acute myeloid leukemias to lovastatin-induced apoptosis: A potential therapeutic approach. , 1999, Blood.
[36] D. Proudfoot,et al. Monocyte prostaglandins inhibit procollagen secretion by human vascular smooth muscle cells: implications for plaque stability. , 1999, Atherosclerosis.
[37] K. Kario,et al. Lipid-lowering therapy corrects endothelial cell dysfunction in a short time but does not affect hypercoagulable state even after long-term use in hyperlipidemic patients. , 1999, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.
[38] M. Fenchel,et al. Effect of HMG-CoA reductase inhibitors on extracellular matrix expression in human vascular smooth muscle cells , 1999, Basic Research in Cardiology.
[39] R. Caldwell,et al. Pravastatin sodium activates endothelial nitric oxide synthase independent of its cholesterol-lowering actions. , 1999, Journal of the American College of Cardiology.
[40] E. Tremoli,et al. Tissue factor in atherosclerosis. , 1999, Atherosclerosis.
[41] P. Meraj,et al. Gender differences in blood thrombogenicity in hyperlipidemic patients and response to pravastatin. , 1999, The American journal of cardiology.
[42] L. Naumovski,et al. Vascular cell apoptosis: cell type-specific modulation by transforming growth factor-beta1 in endothelial cells versus smooth muscle cells. , 1999, Circulation.
[43] L. Badimón,et al. Platelet deposition on eroded vessel walls at a stenotic shear rate is inhibited by lipid-lowering treatment with atorvastatin. , 1999, Arteriosclerosis, thrombosis, and vascular biology.
[44] J. Tardif,et al. Cholesterol reduction rapidly improves endothelial function after acute coronary syndromes. The RECIFE (reduction of cholesterol in ischemia and function of the endothelium) trial. , 1999, Circulation.
[45] A. Gottsäter,et al. Increasing plasma fibrinogen, but unchanged levels of intraplatelet cyclic nucleotides, plasma endothelin-1, factor VII, and neopterin during cholesterol lowering with fluvastatin. , 1999, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.
[46] A. Szczeklik,et al. Inhibition of thrombin generation by simvastatin and lack of additive effects of aspirin in patients with marked hypercholesterolemia. , 1999, Journal of the American College of Cardiology.
[47] M. Pfeffer,et al. Long-Term Effects of Pravastatin on Plasma Concentration of C-reactive Protein , 1999 .
[48] H. Ravn,et al. Plaque pathology and coronary thrombosis in the pathogenesis of acute coronary syndromes. , 1999, Scandinavian journal of clinical and laboratory investigation. Supplementum.
[49] Toshio Hayashi,et al. A HMG-CoA reductase inhibitor improved regression of atherosclerosis in the rabbit aorta without affecting serum lipid levels: possible relevance of up-regulation of endothelial NO synthase mRNA. , 1999, Biochemical and biophysical research communications.
[50] L. Badimón,et al. Nitric oxide synthase II (NOS II) gene expression correlates with atherosclerotic intimal thickening. Preventive effects of HMG-CoA reductase inhibitors. , 1999, Atherosclerosis.
[51] E. Janus,et al. Effects of fluvastatin on prothrombotic and fibrinolytic factors in type 2 diabetes mellitus. , 1999, The American journal of cardiology.